Evolution in Clinical Trials Seminar - 31st October

Posted:
6
October 2005

Phase I trials have evolvedEU Legislative developments have redefined the boundaries of Phase I and opened a new era of opportunity to expedite compounds through the Early Phases. Pharmacology and patient studies can now be integrated or work independently of one another. Clinical & therapeutic innovations now enable Early Phase research to deliver more dynamic and insightful studies, maximizing the probability of a compound reaching the later Phases. We have put together the definitive one-day seminar to explore the new boundaries of Phase I.Click here for more information

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more